Abstract
Introduction
Cardiovascular complications are the most common cause of morbidity and mortality in diabetic patients. The presence of myocardial left ventricular dysfunction (both diastolic and later systolic one) independent of atherosclerosis, coronary artery disease in diabetes, defined as 'diabetic cardiomyopathy', has been well documented in both human beings and animals [1, 2] . The mechanisms of diabetic cardiac dysfunction are multiple and may involve increased oxidative/nitrosative stress [3] [4] [5] [6] , and activation of its downstream effector pathways (e.g. poly(ADP-ribose) polymerase (PARP)) [7, 8] , apoptosis [3, 9, 10] , changes in the composition of extracellular matrix with enhanced cardiac fibrosis and increased inflammation [11, 12] . [13] [14] [15] [16] [17] ; reviewed in [18] [19] [20] ). The XO inhibitor allopurinol (ALP) and its active metabolite oxypurinol showed multitude of beneficial effects in the treatment of these conditions both in experimental animal models and in smallscale human clinical trials [20] . In this study, we tested the effect of ALP on cardiac dysfunction, oxidative-nitrosative stress, apoptosis, PARP activity and fibrosis associated with diabetic cardiomyopathy using a mouse model of type 1 diabetes. Fig. 2A) . Similar change was observed with the mRNA expression of XO in the myocardium (Fig. 1B) . However, XO activity was markedly elevated in the liver, heart and serum of diabetic animals when compared with controls; and this increase was attenuated by ALP (Fig. 2C) . Fig. 3A and B) when compared with myocardium from control mice (Fig. 3A and B) . ALP attenuated increased superoxide/ROS generation in hearts of diabetic animals, but not in controls. (Fig. 3A and B) .
An increasing number of researchers during the past decade have suggested that xanthine oxidase (XO)-derived superoxide

Materials and methods
Animals and treatment
Fig. 2 Effects of diabetes and allopurinol (ALP) on myocardial, liver and serum xanthine oxidase (XO) expression and/or activity. Mice were treated as described in the Methods section and 10 weeks later, animals were killed and hearts were excised. Then protein extracts were subjected to Western blot analysis for the determination of XO expression in the heart and liver tissues. (A) Western blot for XO expression in the liver and heart tissues. The bottom panel denotes the quantification of XO expression. The XO expression was unaltered in untreated or ALP treated diabetic mice (n ϭ 3 in each group). (B) Denotes the mRNA expression of XO in the myocardial tissues in the respective groups as indicated (n ϭ 6-8 in each group
Effects of diabetes and ALP on superoxide/ROS production in the myocardium of diabetic mice
XO-induced superoxide/ROS generation was determined in the frozen section of myocardial tissues using the DHE fluorescence as described in the Methods section. Our observation revealed markedly increased DHE oxidation fluorescence in the diabetic myocardial tissues (
Effects of diabetes and ALP on the mRNA expression of NADP(H) oxidase subunits
It has been demonstrated earlier that in diabetic vascular complications there is significant increase in the superoxide production attributed to the NADPH oxidase activation [25] . Therefore, we (Fig. 4) .
Effects of diabetes and ALP on myocardial eNOS and iNOS expressions
There was no change in the eNOS expression the hearts of either diabetic mice or diabetic mice treated with ALP (Fig. 5A) . On the contrary, iNOS expression was markedly induced ~2.5-fold in diabetic hearts when compared with control mice (Fig. 5B) , which was significantly attenuated by the ALP treatment.
Effect of diabetes and ALP on myocardial 3-NT accumulation
The myocardial 3-NT accumulation (a foot-print of peroxynitrite formation or more broadly nitrosative stress [26] [27] [28] ) in the heart tissues was determined by immunohistochemical staining and quantitative ELISA. As shown in Fig. 6A , diffuse 3-NT accumulation was significantly higher in the myocardium of diabetic mice compared with controls. ALP treatment of diabetic mice attenuated the 3-NT accumulation in heart sections (Fig. 6A) . Similar results were obtained using quantitative ELISA (Fig. 6B) .
Effect of diabetes and ALP on myocardial apoptosis and PARP activity
Western blot analysis (Fig. 7A ) and quantitative determination of caspase 3/7 activity by ELISA (Fig. 7B) (Fig. 7A  and B ). There were also markedly increased mRNA expressions of caspase 3 and 7 in diabetic hearts, which were attenuated by ALP treatment (Fig. 7C.) Myocardial chromatin fragmentation and PARP activity were also elevated in hearts from diabetic mice ( Fig. 7D and E ), which were attenuated by ALP treatment.
Effect of diabetes and ALP on myocardial fibrosis
Sirius red staining of the formalin fixed heart sections revealed marked interstitial fibrosis in the diabetic myocardium characterized by increased collagen accumulation, which was attenuated by ALP treatment (Fig. 8A) . As shown in Fig. 8B -E, mRNA expression of transforming growth factor-beta (TGF-␤; Fig. 8B ), connective tissue growth factor (CTGF; Fig. 8C ), collagen-1 (Fig. 8D) and fibronectin (Fig. 8E) [1, 2] . [3, 7, 11, 29, 30] of the above-mentioned pathways [6, 31] . The cellular sources of superoxide anion in diabetes are multiple and may include NAD(P)H and XO, the mitochondrial respiratory chain among many others [19, 20, 31] . Recent studies suggest that XO may play an important role in the generation of free radicals in diabetes. There is an elevation the plasma and liver XO levels in type 1 diabetic patients [32] and increased endothelial superoxide formation in aorta from alloxan-induced diabetic rabbits can be blocked by the XO inhibitor ALP [32] . Diabetes also causes an increase of XO activity in the liver of rats, and XO is released from the liver of these animals [32] . [28, 35] . Small amount of peroxynitrite may be generated in normal cells and may play various physiological regulatory functions (e.g. in signalling processes; for reviews see [36] [37] [38] [6, 39, 40] and other complications [41] both in experimental animals and in human beings. For example, the degree of cell death and/or dysfunction correlates with levels of NT in endothelial cells, cardiomyocytes and fibroblasts from myocardial biopsies of diabetic patients [9] , hearts of experimental diabetic rats or mice [3, 9, 29] and hearts perfused with high glucose concentrations [5] . The NT immunoreactivity is increased in the microvasculature of type 2 diabetic patients and correlates with fasting blood glucose, HbA1c, intracellular adhesion molecule, vascular cellular adhesion molecule and endothelial dysfunction [42] . Peroxynitrite has been reported to attack various biomolecules, leading to compromised cardiovascular function and cell death (both apoptotic and necrotic) in hearts and other tissues via multiple complex mechanisms [6, 27, 28] . One of these pathways involves DNA strand breakage and consequent activation of the nuclear enzyme PARP, which emerges as a major effector pathway in the development of various interrelated diabetic complications [8, 43] , including cardiomyopathy [7] . Consistently with the importance of these pathways in the development of diabetic cardiomyopathy, [20, 44] ), is particularly encouraging from the therapeutic point of view forecasting multiple possible benefits of ALP treatment in diabetic patients.
The current study demonstrates that STZ-induced diabetes in mice is associated with a marked depression of both systolic and diastolic function of the left ventricle. These results are consistent with earlier reports showing depressed cardiac function in different mouse
